Established and Emerging Biotech ClustersBusiness InsightsSeptember 6, 2011 7 Pages - SKU: RET6647625 |
| Countries covered: Global There has been widespread interest in establishing geographically focused clusters of biotechnology companies and related organizations. It is important for all stakeholders to understand the capabilities of different clusters across the world. Careful alignment of location strategies with the strengths of the various clusters ensures that maximum value can be derived from participation. Understand the key components of a successful biotech cluster and the prevailing trends in biotech research that influence how clusters operate. Gain an overview of key decision making criteria when developing location strategies for research and development. Compare the most prominent areas of expertise within different clusters across the world and identify core strengths. Assess detailed profiles of 41 clusters in both established and emerging locations, and identify key participants and funding sources. View how clusters rank when scored by patenting activity, publications, company presence, industry-academia partnerships, and policy environment. The plentiful government funding, the mature VC sector, the favorable policy environment, and the strong entrepreneurial culture all make the US a leading destination for biotechnology research. The top three US clusters - namely San Francisco, San Diego, and Boston - outscore the rest of the established biotech clusters by a large margin. Among the emerging clusters, Australia’s Melbourne cluster (ranked 24th overall) dominates the group, based on its favorable policy and regulatory environment, especially in clinical trials. The Melbourne cluster has also seen a high amount of collaborative activity with international pharmaceutical companies. VC funding is becoming difficult to obtain, especially for early stage companies. The total innovation capital decreased to $11.3bn in 2010, down by 19% compared with 2006. In addition, the upfront payment components of these financings have reduced by more than 54%, further shrinking the innovation capital available to start-up companies. How do the many biotech clusters of the world compare when ranked against each other? What are the key criteria that should be considered when choosing a location to conduct research in specific areas of drug discovery? What are the crucial components of a successful biotechnology cluster and what characteristics have led to serial innovation? What are the typical commercial rental rates likely to be charged within various biotech clusters across the world? Which are the most important academic institutions and companies in a particular region that present attractive opportunities for collaboration? Please note: this is delivered as a Zip file. |
More Global Research & Development Reports
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by
Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...
Global Biotechnology by
IBISWorld
Global Biotechnology Biotechnology is the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living ...
Global Protein Therapeutics Market Forecast to 2015 by
RNCOS
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most ...
Global Pharmaceuticals, Biotechnology & Life Sciences by
MarketLine
Introduction Global Pharmaceuticals, Biotechnology & Life Sciences industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to ...
Biotechnology by
Global Industry Analysts
The global outlook series on Biotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird’s ...
See all reports like this >>
